SpringWorks Therapeutics to Present at Upcoming Investor Conferences
22 Fevereiro 2024 - 9:00AM
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage
biopharmaceutical company focused on severe rare diseases and
cancer, today announced that management will present at the
following investor conferences:
- TD Cowen 44th Annual Health Care Conference on Monday, March 4
at 2:50 p.m. E.T.
- Barclays 26th Annual Global Healthcare Conference on Tuesday,
March 12 at 9:00 a.m. E.T.
Webcasts of these events will be available on the Events &
Presentations page within the Investors & Media section of the
company’s website at https://ir.springworkstx.com. Replays of the
webcasts will be available on SpringWorks’ website for a limited
time following each conference.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company
applying a precision medicine approach to developing and delivering
life-changing medicines for people with severe rare diseases and
cancer.
Founded in 2017, SpringWorks has a diversified targeted oncology
pipeline spanning solid tumors and hematological cancers, including
clinical trials in rare tumor types and highly prevalent,
genetically defined cancers. OGSIVEO™, approved in the United
States for the treatment of adult patients with progressing desmoid
tumors who require systemic treatment, is SpringWorks’ first
FDA-approved therapy. SpringWorks’ strategic approach and
operational excellence in clinical development have enabled it to
rapidly advance its lead product candidates into late-stage trials
and enter into multiple collaborations with innovators in industry
and academia to unlock the full potential for its portfolio and
create more solutions for patients with cancer.
For more information, visit www.springworkstx.com and
follow @SpringWorksTx on X (formerly Twitter), LinkedIn,
and YouTube.
Contacts:Kim DiamondVice President,
Communications and Investor Relations Phone: 203-561-1646
Email: kdiamond@springworkstx.com
Samantha Hilson Sandler Senior Director, Investor
Relations Phone: 203-461-5501 Email:
samantha.sandler@springworkstx.com
SpringWorks Therapeutics (NASDAQ:SWTX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
SpringWorks Therapeutics (NASDAQ:SWTX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024